{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:38Z","timestamp":1792083638358,"version":"4.4.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Although buprenorphine is highly effective at preventing overdose, access is limited in rural areas. Rural primary care is a critical site to expand access; prescribing support tailored for this setting is urgently needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To test the feasibility and preliminary effectiveness of a brief buprenorphine prescribing support program (BPSP) tailored for rural primary care professionals (PCPs).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cluster randomized pilot clinical trial compared 27 Ohio community health centers with 63 PCPs (10 physicians, 50 nurse practitioners, and 3 physician assistants) receiving the support program at baseline and immediately after the intervention with those receiving only copies of the American Society of Addiction Medicine\u2019s buprenorphine prescribing guidelines. Data were collected from July 25, 2024, to February 28, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The BPSP is a brief, hour-long, asynchronous and online training program, followed by an optional, live booster session, that provides clinical skills on buprenorphine prescribing, addresses misinformation on the safety of buprenorphine, and addresses stigma toward buprenorphine. Health centers were randomized with 2 centers allocated to the intervention for every 1 allocated to the control condition.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary implementation outcomes were feasibility (measured via the 4-item Feasibility of Intervention Measure [scale of 1 to 5, with higher scores indicating greater feasibility]), acceptability (measured via the 4-item Acceptability of Intervention Measure [scale of 1 to 5, with lhigher scores indicating greater acceptability]), and appropriateness (measured via the 4-item Intervention Appropriateness Measure [scale of 1 to 5, with higher scores indicating greater appropriateness]) of the BPSP; willingness to treat opioid use disorder (OUD) in primary care (using a measure developed and tested with a different sample of PCPs); and likelihood of prescribing buprenorphine in the next 6 months (measured via a 5-point Likert scale ranging from 1.00 [extremely unlikely] to 5.00 [extremely likely]).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 63 participating PCPs, 48 participants were allocated to the intervention condition and 15 to the control condition (49 female [78%]; mean [SD] age, 45.5 [11.4] years). Forty-nine participants (78%) practiced in rural areas and 10 (16%) had ever prescribed buprenorphine. Participants receiving the BPSP rated it as highly feasible (median score,\u20094.25 [IQR, 4.00-5.00]), acceptable (median score, 4.88 of 5.00 [IQR, 4.00-5.00]), and appropriate (median score, 5.00 of 5.00 [IQR, 4.00-5.00]). Participants receiving the BPSP had significantly higher willingness to treat OUD; 86% of rank comparisons improved post intervention. Intention to prescribe buprenorphine in the next 6 months also significantly increased; 98% of rank comparisons improved post intervention. Participants who completed the BPSP showed significant improvements in having correct information about buprenorphine, had greater confidence treating addiction and prescribing buprenorphine, and had lower stigma and greater empathy toward patients with OUD.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cluster randomized clinical trial of the BPSF, brief prescribing support was feasible, acceptable, and appropriate for implementation in rural primary care, and intentions to prescribe buprenorphine increased. A larger trial is needed to confirm preliminary findings.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05505227<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.3050","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:40Z","timestamp":1774452640000},"page":"e263050","source":"Crossref","is-referenced-by-count":3,"title":["Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care"],"prefix":"10.1001","volume":"9","author":[{"given":"Berkeley","family":"Franz","sequence":"first","affiliation":[{"name":"Department of Social Medicine, Ohio University Heritage College of Osteopathic Medicine, Athens"},{"name":"The Institute to Advance Population Health, Athens, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay Y.","family":"Dhanani","sequence":"additional","affiliation":[{"name":"School of Management and Labor Relations, Rutgers University, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brook","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Trent","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Go","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Simon","sequence":"additional","affiliation":[{"name":"Ohio University College of Health Sciences and Professions, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyenne","family":"Fenstemaker","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, Ohio University Heritage College of Osteopathic Medicine, Athens"},{"name":"The Institute to Advance Population Health, Athens, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"2","key":"zoi260127r1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/08897077.2015.1010032","article-title":"A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice.","volume":"36","author":"Mueller","year":"2015","journal-title":"Subst Abus"},{"issue":"1","key":"zoi260127r2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amepre.2023.01.037","article-title":"Buprenorphine after nonfatal opioid overdose: reduced mortality risk in Medicare disability beneficiaries.","volume":"65","author":"Samples","year":"2023","journal-title":"Am J Prev Med"},{"issue":"8","key":"zoi260127r3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes.","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"25","key":"zoi260127r4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates\u2014United States, 2022.","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi260127r5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update.","volume":"35","author":"Andrilla","year":"2019","journal-title":"J Rural Health"},{"issue":"5","key":"zoi260127r7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and management of opioid use disorder in primary care: an update.","volume":"22","author":"Donroe","year":"2020","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"zoi260127r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 Waiver.","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi260127r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209633","article-title":"Different forms of stigma and rural primary care professionals\u2019 willingness to prescribe buprenorphine.","volume":"171","author":"Franz","year":"2025","journal-title":"J Subst Use Addict Treat"},{"issue":"5","key":"zoi260127r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4561","article-title":"Barriers and facilitators to clinician readiness to provide emergency department-initiated buprenorphine.","volume":"3","author":"Hawk","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260127r11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/jrh.12832","article-title":"Primary care professionals\u2019 perspectives on tailoring buprenorphine training for rural practice.","volume":"40","author":"Fenstemaker","year":"2024","journal-title":"J Rural Health"},{"key":"zoi260127r12","doi-asserted-by":"publisher","DOI":"10.1177\/29767342251376812","article-title":"Peer prescriber support strategies to increase buprenorphine prescribing in primary care.","author":"King","year":"2025","journal-title":"Subst Use Addctn J"},{"issue":"12","key":"zoi260127r13","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s11606-024-09260-1","article-title":"The implementation climate for integrating buprenorphine prescribing into rural primary care.","volume":"40","author":"Fenstemaker","year":"2025","journal-title":"J Gen Intern Med"},{"key":"zoi260127r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104381","article-title":"Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: an interrupted time series analysis.","volume":"126","author":"Roy","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi260127r16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ajad.13260","article-title":"Are X-Waiver trainings enough? facilitators and barriers to buprenorphine prescribing after X-Waiver trainings.","volume":"31","author":"Gordon","year":"2022","journal-title":"Am J Addict"},{"issue":"3","key":"zoi260127r17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/29767342241303583","article-title":"Examining the impact of eliminating the X Waiver on buprenorphine dispensation in 63 counties in Pennsylvania.","volume":"46","author":"Bilden","year":"2025","journal-title":"Subst Use Addctn J"},{"key":"zoi260127r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmmh.2023.100263","article-title":"Positive contact and empathy as predictors of primary care providers\u2019 willingness to prescribe medications for opioid use disorder.","volume":"4","author":"Dhanani","year":"2023","journal-title":"SSM Ment Health"},{"issue":"1","key":"zoi260127r19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1360-0443.2011.03601.x","article-title":"The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review.","volume":"107","author":"Livingston","year":"2012","journal-title":"Addiction"},{"issue":"2","key":"zoi260127r21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment.","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"issue":"1","key":"zoi260127r26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1108\/13665620610641300","article-title":"The impact of cognitive dissonance on learning work behavior.","volume":"18","author":"Dechawatanapaisal","year":"2006","journal-title":"J Workplace Learn"},{"issue":"1","key":"zoi260127r27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures.","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement Sci"},{"issue":"1","key":"zoi260127r28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13722-021-00242-w","article-title":"Physician blame and vulnerability: novel predictors of physician willingness to work with patients who misuse opioids.","volume":"16","author":"Franz","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"zoi260127r29","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2399316","article-title":"Knowledge of medications for opioid use disorder and associated stigma among primary care professionals.","volume":"56","author":"Piscalko","year":"2024","journal-title":"Ann Med"},{"issue":"1","key":"zoi260127r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-024-00436-y","article-title":"Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.","volume":"19","author":"Franz","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"zoi260127r31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1747-597X-8-17","article-title":"Physicians\u2019 attitudes toward unhealthy alcohol use and self-efficacy for screening and counseling as predictors of their counseling and primary care patients\u2019 drinking outcomes.","volume":"8","author":"Elwy","year":"2013","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"zoi260127r32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2016.05.007","article-title":"Attitudes, perceptions and practice of alcohol and drug screening, brief intervention and referral to treatment: a case study of New York State primary care physicians and non-physician providers.","volume":"139","author":"Harris","year":"2016","journal-title":"Public Health"},{"issue":"1","key":"zoi260127r33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1037\/0022-3514.55.1.52","article-title":"Five studies testing two new egoistic alternatives to the empathy-altruism hypothesis.","volume":"55","author":"Batson","year":"1988","journal-title":"J Pers Soc Psychol"},{"key":"zoi260127r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2021.100372","article-title":"Revisiting the relationship between contact and physician attitudes toward patients with opioid use disorder.","volume":"14","author":"Dhanani","year":"2021","journal-title":"Addict Behav Rep"},{"issue":"8","key":"zoi260127r35","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1176\/appi.ps.202000529","article-title":"Rural-urban differences in physician bias toward patients with opioid use disorder.","volume":"72","author":"Franz","year":"2021","journal-title":"Psychiatr Serv"},{"issue":"5","key":"zoi260127r37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpsychires.2010.10.008","article-title":"The role and interpretation of pilot studies in clinical research.","volume":"45","author":"Leon","year":"2011","journal-title":"J Psychiatr Res"},{"issue":"2","key":"zoi260127r38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40596-015-0391-0","article-title":"Managing stigma effectively: what social psychology and social neuroscience can teach us.","volume":"40","author":"Griffith","year":"2016","journal-title":"Acad Psychiatry"},{"issue":"1","key":"zoi260127r39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08964289.2018.1555129","article-title":"Substance use stigma, primary care, and the New York State Prescription Drug Monitoring Program.","volume":"46","author":"Allen","year":"2020","journal-title":"Behav Med"},{"key":"zoi260127r40","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1370\/afm.2920","article-title":"Impact of stigma on clinician training for opioid use disorder care: a qualitative study in a primary care learning collaborative.","volume":"21","author":"Klusaritz","year":"2023","journal-title":"Ann Fam Med"},{"key":"zoi260127r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108627","article-title":"The role of stigma in US primary care physicians\u2019 treatment of opioid use disorder.","volume":"221","author":"Stone","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi260127r42","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review.","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"key":"zoi260127r43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1062096","article-title":"The worrying, current state of addictions training in medicine.","volume":"9","author":"Lundin","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"zoi260127r44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11414-020-09706-4","article-title":"Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use.","volume":"47","author":"Jacobson","year":"2020","journal-title":"J Behav Health Serv Res"},{"key":"zoi260127r45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1184951","article-title":"A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder.","volume":"14","author":"Becker","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi260127r46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1370\/afm.1312","article-title":"Systematic review and meta-analysis of practice facilitation within primary care settings.","volume":"10","author":"Baskerville","year":"2012","journal-title":"Ann Fam Med"},{"issue":"6","key":"zoi260127r47","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment.","volume":"54","author":"Haffajee","year":"2018","journal-title":"Am J Prev Med"},{"key":"zoi260127r24","volume-title":"The Nature of Prejudice: 25th Anniversary Edition","author":"Allport","year":"1979"},{"key":"zoi260127r6","unstructured":"Defining the PCMH. Agency for Healthcare Research and Quality. Reviewed August 2022. Accessed July 15, 2025. https:\/\/www.ahrq.gov\/ncepcr\/research\/care-coordination\/pcmh\/define.html"},{"key":"zoi260127r15","unstructured":"Medications for opioid use disorder: 8-hour options. Providers Clinical Support System. Accessed July 15, 2025. https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/"},{"key":"zoi260127r20","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder\u20142020 focused update. American Society of Addiction Medicine. Accessed April 12, 2023. https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline"},{"key":"zoi260127r22","unstructured":"Aronowitz? SV, Behrends? CN, Lowenstein? M, Schackman? B, Weiner? J. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach. Penn LDI CHERISH. January 27, 2022. Accessed February 5, 2025. https:\/\/repository.upenn.edu\/entities\/publication\/03d3583b-cb4f-483b-8eba-3648f1ffa06f"},{"key":"zoi260127r23","unstructured":"Friedman? HS, Markey? CH, eds. Encyclopedia of Mental Health. 3rd ed. Academic Press; 2023. Accessed March 16, 2025. http:\/\/www.sciencedirect.com:5070\/referencework\/9780323914987\/encyclopedia-of-mental-health"},{"key":"zoi260127r25","unstructured":"Festinger? L. A Theory of Cognitive Dissonance. Stanford University Press; 1957. Accessed March 16, 2025. https:\/\/psycnet.apa.org\/record\/1993-97948-000"},{"key":"zoi260127r36","unstructured":"Ohio\u2019s rural and urban counties. Ohio Department of Health Primary Care Office. 2020. Accessed July 19, 2025. https:\/\/www.ohioruralhealth.org\/upload\/2020_rural_and_urban_counties.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846941\/franz_2026_oi_260127_1773848830.4978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:46Z","timestamp":1774452646000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846941"}},"subtitle":["A Cluster Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.3050","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}